Oxana Beskrovnaya

Chief Innovation Officer; Former Chief Scientific OfficeratDyne Therapeutics· In proxies 2022–2025

Pay in FY2024+92% from the year before · Dyne Therapeutics stock +77.1% the same year

Oxana Beskrovnaya was paid $3.8M in FY2024 (Dec), up 92%. Dyne Therapeutics stock rose 77.1% that year.

Pay$100 in the stock at the end of FY21 → $198

Pay is from the Summary Compensation Table of each Dyne Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

DYN
Dyne TherapeuticsPublic company · 4 yr
- Chief Innovation Officer; Former Chief Scientific Officer2022 – Present · 4 yrStock in role +34%

Roles come from the proxy statements of each company.

Activity

Pay
Dyne Therapeutics Chief Innovation Officer; Former Chief Scientific Officer pay rose 92% to $3.8M. The stock rose 77% in FY2024 (Dec).
DEF 14AApr 15, 2025
Pay
Dyne Therapeutics Chief Innovation Officer; Former Chief Scientific Officer pay rose 34% to $2.0M. The stock rose 15% in FY2023 (Dec).
DEF 14AApr 15, 2025

For the press:Download CSV Download PNG How to use our data

Two people shown as one, or a wrong number?